Skip NavigationSkip to Content

New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: Synthesis, resolution, and inhibitory activity

  1. Author:
    Krajewski, K.
    Zhang, Y. J.
    Parrish, D.
    Deschamps, J.
    Roller, P. P.
    Pathak, V. K.
  2. Author Address

    NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA. NCI, Med Chem Lab, CCR, NIH, Frederick, MD 21702 USA. USN, Res Lab, Washington, DC 20375 USA.;Roller, PP, NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA.;proll@helix.nih.gov vpathak@ncifcrf.gov
    1. Year: 2006
    2. Date: Jun
  1. Journal: Bioorganic & Medicinal Chemistry Letters
    1. 16
    2. 11
    3. Pages: 3034-3038
  2. Type of Article: Article
  3. ISSN: 0960-894X
  1. Abstract:

    We synthesized, separated into enantiomers, and tested for the HIV-1 reverse transcriptase inhibitory activity a group Of analogs of dimethyl-1-(1-piperidynyl)cyclobuta[b][1]benzothiophene-2,2a(7bH)-dicarb oxylate (NSC-380292). Absolute configurations of the enantiomers were determined based on absolute X-ray structures and analysis of CD spectra. Within pairs of enantiomers the (R,R)-enantiomer was always much more potent HIV-1 reverse transcriptase inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.bmcl.2006.02.049
  2. WOS: 000237407800044

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel